JP2001518304A - アンギオスタチン成分を含む融合タンパク質及び抗腫瘍療法におけるその使用 - Google Patents

アンギオスタチン成分を含む融合タンパク質及び抗腫瘍療法におけるその使用

Info

Publication number
JP2001518304A
JP2001518304A JP2000513958A JP2000513958A JP2001518304A JP 2001518304 A JP2001518304 A JP 2001518304A JP 2000513958 A JP2000513958 A JP 2000513958A JP 2000513958 A JP2000513958 A JP 2000513958A JP 2001518304 A JP2001518304 A JP 2001518304A
Authority
JP
Japan
Prior art keywords
seq
protein
multifunctional protein
angiostatin
interferon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000513958A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001518304A5 (cg-RX-API-DMAC7.html
Inventor
ボラノウスキ,マーク・エイ
キャパロン,メイアー・エイチ
キャスパーソン,ジェラルド・エフ
グレゴリー,スーザン・エイ
クレイン,バーバラ・ケイ
マッカーン,ジョン・ピー
Original Assignee
ジー・ディー・サール・アンド・カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジー・ディー・サール・アンド・カンパニー filed Critical ジー・ディー・サール・アンド・カンパニー
Publication of JP2001518304A publication Critical patent/JP2001518304A/ja
Publication of JP2001518304A5 publication Critical patent/JP2001518304A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2000513958A 1997-10-01 1998-09-30 アンギオスタチン成分を含む融合タンパク質及び抗腫瘍療法におけるその使用 Withdrawn JP2001518304A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6060997P 1997-10-01 1997-10-01
US60/060,609 1997-10-01
PCT/US1998/020464 WO1999016889A1 (en) 1997-10-01 1998-09-30 Fusion proteins comprising an angiostatin moiety and their use in anti-tumor treatment

Publications (2)

Publication Number Publication Date
JP2001518304A true JP2001518304A (ja) 2001-10-16
JP2001518304A5 JP2001518304A5 (cg-RX-API-DMAC7.html) 2006-01-05

Family

ID=22030604

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000513958A Withdrawn JP2001518304A (ja) 1997-10-01 1998-09-30 アンギオスタチン成分を含む融合タンパク質及び抗腫瘍療法におけるその使用

Country Status (5)

Country Link
EP (2) EP1019515A1 (cg-RX-API-DMAC7.html)
JP (1) JP2001518304A (cg-RX-API-DMAC7.html)
AU (1) AU9673998A (cg-RX-API-DMAC7.html)
CA (1) CA2303401A1 (cg-RX-API-DMAC7.html)
WO (1) WO1999016889A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029856A1 (en) * 1997-12-08 1999-06-17 Beth Israel Deaconess Medical Center Restin and methods of use thereof
US6797488B1 (en) 1997-12-08 2004-09-28 Beth Israel Deaconess Medical Center Methods of producing anti-angiogenic proteins
WO1999061464A1 (en) * 1998-05-28 1999-12-02 Korea Green Cross Corporation Process of purifying angiogenesis inhibitors
US6500431B1 (en) * 1998-07-13 2002-12-31 University Of Southern California Inhibitors of angiogenesis and tumor growth
CA2367375A1 (en) * 1999-03-15 2000-09-21 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
AU2004240199B2 (en) * 1999-04-30 2007-05-17 Novartis Vaccines And Diagnostics S.R.L. Conserved Neisserial antigens
AU2001238499A1 (en) * 2000-02-18 2001-08-27 New York Medical College Nitroacridine/tumor inhibitor compositions
AU8591901A (en) 2000-09-05 2002-03-22 Karolinska Innovations Ab Materials and methods relating to endothelial cell growth inhibitors
DE60134885D1 (de) * 2000-11-28 2008-08-28 David M Waisman Antiangiogene polypeptide
US20030086903A1 (en) 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
WO2003093303A1 (en) 2002-05-06 2003-11-13 Board Of Regents, The University Of Texas System Targeting proteins to deliver therapeutic or diagnostic reagents
JP4511108B2 (ja) * 2002-05-31 2010-07-28 オンコリクス インコーポレイテッド ヒトプロラクチン拮抗剤−血管新生阻害剤融合蛋白質
CA2514873C (en) 2002-12-13 2012-01-03 David Waisman Compositions and methods for inhibiting tumor growth and metastasis
WO2008124086A2 (en) * 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
EP2628748A1 (en) 2012-02-14 2013-08-21 Szilak Laboratories Bioinformatics & Molecule-Design Ltd. Angiostatin chimeras and uses thereof
TWI698240B (zh) 2012-05-15 2020-07-11 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
ES2686968T3 (es) * 2013-05-06 2018-10-23 China Pharmaceutical University Proteínas de fusión bifuncionales para inhibir la angiogénesis en el microambiente tumoral y para activar las respuestas inmunitarias adaptativas y los genes y usos de las mismas
ES2822551T3 (es) 2014-03-17 2021-05-04 Adverum Biotechnologies Inc Composiciones y métodos para la expresión génica mejorada en células de los conos
WO2015168474A1 (en) 2014-04-30 2015-11-05 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
FI3265178T3 (fi) 2015-03-02 2026-08-03 Adverum Biotechnologies Inc Koostumuksia ja menetelmiä polynukleotidien viemiseksi intravitreaalisesti retinaalisiin tappisoluihin
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
CN114058636A (zh) * 2021-11-16 2022-02-18 大连润生康泰医学检验实验室有限公司 一种转甲状腺素蛋白基因的克隆、表达与纯化方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8315980D0 (en) * 1983-06-10 1983-07-13 Biogen Nv Producing hybrid dna sequences
IL86909A0 (en) * 1987-07-01 1988-11-30 Beecham Group Plc Hybrid plasminogen activator,dna coding therefor,derivatives of said plasminogen activator and pharmaceutical compositions containing said plasminogen activator or said derivatives
AU1674292A (en) * 1991-03-15 1992-10-21 Synergen, Inc. Pegylation of polypeptides
CN1636594B (zh) * 1994-04-26 2012-08-29 儿童医学中心公司 血管生成抑制素和用于抑制血管生成的方法
MX9708217A (es) * 1995-04-26 1997-12-31 Childrens Medical Center Fragmentos de angiostatina y angiostatina agregada y metodos de uso.
US5824299A (en) * 1995-06-22 1998-10-20 President & Fellows Of Harvard College Modulation of endothelial cell proliferation with IP-10
EP0857210B1 (en) * 1995-10-23 2003-09-03 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
US5837680A (en) * 1996-02-16 1998-11-17 Children's Medical Center Corporation Pharmaceutical compositions comprising troponin subunits, fragments and analogs thereof and methods of their use to inhibit angiogenesis
JP2002523036A (ja) * 1998-08-25 2002-07-30 レキシジェン ファーマシューティカルズ コーポレイション イムノフュージンとしての新脈管形成インヒビターの発現および輸送

Also Published As

Publication number Publication date
WO1999016889A1 (en) 1999-04-08
EP1705248A1 (en) 2006-09-27
AU9673998A (en) 1999-04-23
EP1019515A1 (en) 2000-07-19
CA2303401A1 (en) 1999-04-08

Similar Documents

Publication Publication Date Title
EP1705248A1 (en) Fusion proteins comprising an angiostatin moiety and their use in anti-tumour treatment
RU2240328C2 (ru) Гомодимерный слитый белок, имеющий активность ингибитора ангиогенеза (варианты), молекула днк, кодирующая гомодимерный слитый белок, вектор для экспрессии гомодимерного слитого белка, способ трансфекции клетки млекопитающего и способ получения гомодимерного слитого белка
KR100336452B1 (ko) 앤지오스타틴및맥관형성억제를위한이의사용방법
CN1087344C (zh) 转化生长因子α-H1
JP4295831B2 (ja) 改変された腫瘍壊死因子
JPH11509187A (ja) 内皮細胞増殖の調節
AU749904B2 (en) Restin and methods of use thereof
US20050063948A1 (en) Methods for targeting interleukin-12 to malignant endothelium
CN100543036C (zh) 递送治疗或诊断试剂的导向蛋白质
AU784359B2 (en) Compositions and methods for inhibiting endothelial cell proliferation
US6797488B1 (en) Methods of producing anti-angiogenic proteins
JP2002516261A (ja) セリンプロテアーゼを利用して内皮細胞増殖を阻害し血管新生を調節するための組成物と方法
EP1268798B1 (en) Anti-angiogenic properties of vascostatin and fragments or variants thereof
AU781134B2 (en) Methods for treating tumors using antiangiogenic compounds
EP1268783B1 (en) Antiangiogene Eigenschaften von Matin und Fragmenten oder Varianten davon
JP2000508531A (ja) 細胞外/上皮増殖因子様タンパク質
RO118299B1 (ro) Polipeptida trombopoietina, secventa adn care o codifica, procedeu pentru prepararea polipeptidei trombopoietine si compozitie farmaceutica cu aceasta
US20040121945A1 (en) Compositions and methods for inhibiting endothelial cell proliferation
US20030077818A1 (en) Compositions and methods for targeting interleukin-12 to malignant endothelium
AU2001287274B2 (en) Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains
JP2000506371A (ja) 成長因子htter36
US20030119739A1 (en) Anti-angiogenic and anti-tumor properties of Vascostatin and other nidogen domains
AU2001287274A1 (en) Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains
JP2006087443A (ja) トランスフォーミング増殖因子αHII
JP2009100747A (ja) トランスフォーミング増殖因子αHII

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050930

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050930

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20061012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070307